(Q37821752)

23 August 2017

1 reference

title

The discovery and development of rivaroxaban, an oral, direct factor Xa inhibitor (English)

1 reference

23 August 2017

Elisabeth Perzborn

1

1 reference

23 August 2017

Susanne Roehrig

2

1 reference

23 August 2017

Alexander Straub

3

1 reference

23 August 2017

Dagmar Kubitza

4

1 reference

23 August 2017

Frank Misselwitz

5

1 reference

23 August 2017

publication date

17 December 2010

1 reference

Nature Reviews Drug Discovery

23 August 2017

published in

1 reference

23 August 2017

volume

10

1 reference

23 August 2017

issue

1

1 reference

23 August 2017

page(s)

61-75

1 reference

https://scigraph.springernature.com/pub.10.1038/nrd3185

23 August 2017

exact match

0 references

cites work

Parenteral anticoagulants: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).

1 reference

Treatment and prevention of heparin-induced thrombocytopenia: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).

31 March 2020

1 reference

Orthopaedic thromboprophylaxis: limitations of current guidelines

31 March 2020

1 reference

Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).

31 March 2020

1 reference

Genetic determinants of response to warfarin during initial anticoagulation

31 March 2020

1 reference

Estimation of the warfarin dose with clinical and pharmacogenetic data

31 March 2020

1 reference

31 March 2020

1 reference

Emerging anticoagulants for the treatment of venous thromboembolism

31 March 2020

1 reference

First-in-human experience of an antidote-controlled anticoagulant using RNA aptamer technology: a phase 1a pharmacodynamic evaluation of a drug-antidote pair for the controlled regulation of factor IXa activity

31 March 2020

1 reference

Partial factor IXa inhibition with TTP889 for prevention of venous thromboembolism: an exploratory study

31 March 2020

1 reference

Factor XIa as a possible new target of antithrombotic therapy

31 March 2020

1 reference

Antithrombotic and hemostatic effects of a small molecule factor XIa inhibitor in rats

31 March 2020

1 reference

Ximelagatran: direct thrombin inhibitor

31 March 2020

1 reference

New therapeutic option for thromboembolism--dabigatran etexilate

31 March 2020

1 reference

Fondaparinux, the first selective factor Xa inhibitor

31 March 2020

1 reference

Apixaban, an oral direct Factor Xa inhibitor: awaiting the verdict

31 March 2020

1 reference

Rivaroxaban, an oral direct factor Xa inhibitor

31 March 2020

1 reference

Coagulation factor Xa inhibition: biological background and rationale

31 March 2020

1 reference

Dose-response study of recombinant human soluble thrombomodulin (ART-123) in the prevention of venous thromboembolism after total hip replacement.

31 March 2020

1 reference

Efficacy and safety of recombinant human soluble thrombomodulin (ART-123) in disseminated intravascular coagulation: results of a phase III, randomized, double-blind clinical trial

31 March 2020

1 reference

Efficacy and safety of recombinant human activated protein C for severe sepsis

31 March 2020

1 reference

Recombinant human activated protein C: current insights into its mechanism of action

31 March 2020

1 reference

Factor Xa or thrombin: is factor Xa a better target?

31 March 2020

1 reference

Heterogeneity of synthetic factor Xa inhibitors

31 March 2020

1 reference

Oral, direct factor Xa inhibitors in development for the prevention and treatment of thromboembolic diseases

31 March 2020

1 reference

Diagnosis and treatment of inherited factor X deficiency

31 March 2020

1 reference

Stuart clotting defect. I. Segregation of an hereditary hemorrhagic state from the heterogeneous group heretofore called stable factor (SPCA, proconvertin, factor VII) deficiency

31 March 2020

1 reference

31 March 2020

A new coagulation defect

1 reference

Tick anticoagulant peptide (TAP) is a novel inhibitor of blood coagulation factor Xa

31 March 2020

1 reference

Selective inhibition of factor Xa during thrombolytic therapy markedly improves coronary artery patency in a canine model of coronary thrombosis

31 March 2020

1 reference

Maintenance of canine coronary artery patency following thrombolysis with front loaded plus low dose maintenance conjunctive therapy. A comparison of factor Xa versus thrombin inhibition

31 March 2020

1 reference

Conjunctive enhancement of enzymatic thrombolysis and prevention of thrombotic reocclusion with the selective factor Xa inhibitor, tick anticoagulant peptide. Comparison to hirudin and heparin in a canine model of acute coronary artery thrombosis

31 March 2020

1 reference

Selective Inhibition of Factor Xa Is More Efficient Than Factor VIIa–Tissue Factor Complex Blockade at Facilitating Coronary Thrombolysis in the Canine Model

31 March 2020

1 reference

Importance of factor Xa in determining the procoagulant activity of whole-blood clots

31 March 2020

1 reference

Role of thrombin compared with factor Xa in the procoagulant activity of whole blood clots

31 March 2020

1 reference

Sustained inhibition of whole-blood clot procoagulant activity by inhibition of thrombus-associated factor Xa

31 March 2020

1 reference

Evidence for a rebound coagulation phenomenon after cessation of a 4-hour infusion of a specific thrombin inhibitor in patients with unstable angina pectoris

31 March 2020

1 reference

Reactivation of unstable angina after the discontinuation of heparin

31 March 2020

1 reference

Review of the rebound phenomenon in new anticoagulant treatments

31 March 2020

1 reference

Different antithrombotic properties of factor Xa inhibitor and thrombin inhibitor in rat thrombosis models

31 March 2020

1 reference

YM-60828, a novel factor Xa inhibitor: Separation of its antithrombotic effects from its prolongation of bleeding time

31 March 2020

1 reference

Characteristics of gastrointestinal absorption of DX-9065a, a new synthetic anticoagulant.

31 March 2020

1 reference

First experience with direct, selective factor Xa inhibition in patients with non-ST-elevation acute coronary syndromes: results of the XaNADU-ACS Trial

31 March 2020

1 reference

Review of fondaparinux sodium injection for the prevention of venous thromboembolism in patients undergoing surgery

31 March 2020

1 reference

Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after hip-fracture surgery.

31 March 2020

1 reference

Postoperative fondaparinux versus preoperative enoxaparin for prevention of venous thromboembolism in elective hip-replacement surgery: a randomised double-blind comparison

31 March 2020

1 reference

Postoperative fondaparinux versus postoperative enoxaparin for prevention of venous thromboembolism after elective hip-replacement surgery: a randomised double-blind trial.

31 March 2020

1 reference

Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after elective major knee surgery

31 March 2020

1 reference

Fondaparinux vs enoxaparin for the prevention of venous thromboembolism in major orthopedic surgery: a meta-analysis of 4 randomized double-blind studies.

31 March 2020

1 reference

Discovery of the novel antithrombotic agent 5-chloro-N-({(5S)-2-oxo-3- [4-(3-oxomorpholin-4-yl)phenyl]-1,3-oxazolidin-5-yl}methyl)thiophene- 2-carboxamide (BAY 59-7939): an oral, direct factor Xa inhibitor

31 March 2020

1 reference

Structure-based design of novel guanidine/benzamidine mimics: potent and orally bioavailable factor Xa inhibitors as novel anticoagulants

31 March 2020

1 reference

Discovery of 1-[3-(aminomethyl)phenyl]-N-3-fluoro-2'-(methylsulfonyl)-[1,1'-biphenyl]-4-yl]-3-(trifluoromethyl)-1H-pyrazole-5-carboxamide (DPC423), a highly potent, selective, and orally bioavailable inhibitor of blood coagulation factor Xa.

31 March 2020

1 reference

Crystal structures of two potent nonamidine inhibitors bound to factor Xa

31 March 2020

1 reference

Discovery of an orally efficacious inhibitor of coagulation factor Xa which incorporates a neutral P1 ligand

31 March 2020

1 reference

Molecular structures of human factor Xa complexed with ketopiperazine inhibitors: preference for a neutral group in the S1 pocket

31 March 2020

1 reference

Chlorothiophenecarboxamides as P1 surrogates of inhibitors of blood coagulation factor Xa.

31 March 2020

1 reference

Probing the subpockets of factor Xa reveals two binding modes for inhibitors based on a 2-carboxyindole scaffold: a study combining structure-activity relationship and X-ray crystallography.

31 March 2020

1 reference

In vitro and in vivo studies of the novel antithrombotic agent BAY 59-7939--an oral, direct Factor Xa inhibitor

31 March 2020

1 reference

In vitro inhibition of thrombin generation, after tissue factor pathway activation, by the oral, direct factor Xa inhibitor rivaroxaban

31 March 2020

1 reference

Effects of the oral, direct factor xa inhibitor rivaroxaban on platelet-induced thrombin generation and prothrombinase activity

31 March 2020

1 reference

Prevention and treatment of experimental thrombosis in rabbits with rivaroxaban (BAY 597939)--an oral, direct factor Xa inhibitor

31 March 2020

1 reference

Dose-escalation study of the pharmacokinetics and pharmacodynamics of rivaroxaban in healthy elderly subjects

31 March 2020

1 reference

Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939--an oral, direct Factor Xa inhibitor--after multiple dosing in healthy male subjects

31 March 2020

1 reference

Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct factor Xa inhibitor

31 March 2020

1 reference

Drug interactions evaluation: an integrated part of risk assessment of therapeutics

31 March 2020

1 reference

A regulatory viewpoint on transporter-based drug interactions

31 March 2020

1 reference

Rivaroxaban (BAY 59-7939)--an oral, direct Factor Xa inhibitor--has no clinically relevant interaction with naproxen

31 March 2020

1 reference

Safety, tolerability, pharmacodynamics, and pharmacokinetics of rivaroxaban--an oral, direct factor Xa inhibitor--are not affected by aspirin

31 March 2020

1 reference

Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty

31 March 2020

1 reference

Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial

31 March 2020

1 reference

Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty

31 March 2020

1 reference

Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial

31 March 2020

1 reference

Pharmacokinetics of BAY 59-7939--an oral, direct Factor Xa inhibitor--in rats and dogs

31 March 2020

1 reference

In vitro metabolism of rivaroxaban, an oral, direct factor Xa inhibitor, in liver microsomes and hepatocytes of rats, dogs, and humans

31 March 2020

1 reference

Metabolism and excretion of rivaroxaban, an oral, direct factor Xa inhibitor, in rats, dogs, and humans

31 March 2020

1 reference

Population pharmacokinetics and pharmacodynamics of rivaroxaban--an oral, direct factor Xa inhibitor--in patients undergoing major orthopaedic surgery.

31 March 2020

1 reference

Population model of the pharmacokinetics and pharmacodynamics of rivaroxaban--an oral, direct factor xa inhibitor--in healthy subjects

31 March 2020

1 reference

Body weight has limited influence on the safety, tolerability, pharmacokinetics, or pharmacodynamics of rivaroxaban (BAY 59-7939) in healthy subjects

31 March 2020

1 reference

Effects of renal impairment on the pharmacokinetics, pharmacodynamics and safety of rivaroxaban, an oral, direct Factor Xa inhibitor

31 March 2020

1 reference

Dose-escalation study of rivaroxaban (BAY 59-7939)--an oral, direct Factor Xa inhibitor--for the prevention of venous thromboembolism in patients undergoing total hip replacement

31 March 2020

1 reference

A once-daily, oral, direct Factor Xa inhibitor, rivaroxaban (BAY 59-7939), for thromboprophylaxis after total hip replacement

31 March 2020

1 reference

Oral, direct Factor Xa inhibition with BAY 59-7939 for the prevention of venous thromboembolism after total hip replacement

31 March 2020

1 reference

BAY 59-7939: an oral, direct factor Xa inhibitor for the prevention of venous thromboembolism in patients after total knee replacement. A phase II dose-ranging study

31 March 2020

1 reference

Randomized, double-blind, crossover study to investigate the effect of rivaroxaban on QT-interval prolongation

31 March 2020

1 reference

Association of low protein Z levels with ischemic stroke in young women

31 March 2020

1 reference

Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)

31 March 2020

1 reference

Apixaban or enoxaparin for thromboprophylaxis after knee replacement

31 March 2020

1 reference

Oral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery

31 March 2020

1 reference

Oral rivaroxaban for the prevention of symptomatic venous thromboembolism after elective hip and knee replacement

31 March 2020

1 reference

Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial.

31 March 2020

1 reference

Treatment of Proximal Deep-Vein Thrombosis With the Oral Direct Factor Xa Inhibitor Rivaroxaban (BAY 59-7939): The ODIXa-DVT (Oral Direct Factor Xa Inhibitor BAY 59-7939 in Patients With Acute Symptomatic Deep-Vein Thrombosis) Study

31 March 2020

1 reference

A dose-ranging study evaluating once-daily oral administration of the factor Xa inhibitor rivaroxaban in the treatment of patients with acute symptomatic deep vein thrombosis: the Einstein-DVT Dose-Ranging Study

31 March 2020

1 reference

Oral rivaroxaban for symptomatic venous thromboembolism

31 March 2020

1 reference

Rivaroxaban-once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation: rationale and design of the ROCKET AF study

31 March 2020

1 reference

Apixaban, an oral, direct and highly selective factor Xa inhibitor: in vitro, antithrombotic and antihemostatic studies

31 March 2020

1 reference

Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial

31 March 2020

1 reference

Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) trial.

31 March 2020

1 reference

Rationale and design of AVERROES: apixaban versus acetylsalicylic acid to prevent stroke in atrial fibrillation patients who have failed or are unsuitable for vitamin K antagonist treatment

31 March 2020

1 reference

Apixaban for reduction in stroke and other ThromboemboLic events in atrial fibrillation (ARISTOTLE) trial: design and rationale

31 March 2020

1 reference

Antithrombotic effects of factor Xa inhibition with DU-176b: Phase-I study of an oral, direct factor Xa inhibitor using an ex-vivo flow chamber

31 March 2020

1 reference

A dose-ranging study evaluating the oral factor Xa inhibitor edoxaban for the prevention of venous thromboembolism in patients undergoing total knee arthroplasty

31 March 2020

1 reference

Oral direct factor Xa inhibition with edoxaban for thromboprophylaxis after elective total hip replacement. A randomised double-blind dose-response study.

31 March 2020

1 reference

Randomised, parallel-group, multicentre, multinational phase 2 study comparing edoxaban, an oral factor Xa inhibitor, with warfarin for stroke prevention in patients with atrial fibrillation

31 March 2020

1 reference

Prevention of venous thromboembolism with an oral factor Xa inhibitor, YM150, after total hip arthroplasty. A dose finding study (ONYX-2).

31 March 2020

1 reference

Otamixaban for the treatment of patients with non-ST-elevation acute coronary syndromes (SEPIA-ACS1 TIMI 42): a randomised, double-blind, active-controlled, phase 2 trial

31 March 2020

1 reference

Randomized, double-blind, dose-ranging study of otamixaban, a novel, parenteral, short-acting direct factor Xa inhibitor, in percutaneous coronary intervention: the SEPIA-PCI trial

31 March 2020

1 reference

Development of idraparinux and idrabiotaparinux for anticoagulant therapy.

31 March 2020

1 reference

The pharmacokinetics of idraparinux, a long-acting indirect factor Xa inhibitor: population pharmacokinetic analysis from Phase III clinical trials

31 March 2020

1 reference

Comparison of idraparinux with vitamin K antagonists for prevention of thromboembolism in patients with atrial fibrillation: a randomised, open-label, non-inferiority trial

31 March 2020

1 reference

Idraparinux versus standard therapy for venous thromboembolic disease

31 March 2020

1 reference

Dabigatran versus warfarin in patients with atrial fibrillation

31 March 2020

1 reference

Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial.

31 March 2020

1 reference

Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial.

31 March 2020

1 reference

Dabigatran versus warfarin in the treatment of acute venous thromboembolism

31 March 2020

1 reference

New direct thrombin inhibitors.

31 March 2020

1 reference

Halothiophene benzimidazoles as P1 surrogates of inhibitors of blood coagulation factor Xa.

31 March 2020

1 reference

Discovery of 1-(4-methoxyphenyl)-7-oxo-6-(4-(2-oxopiperidin-1-yl)phenyl)-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide (apixaban, BMS-562247), a highly potent, selective, efficacious, and orally bioavailable inhibitor of blood [...]

31 March 2020

1 reference

The discovery of (2R,4R)-N-(4-chlorophenyl)-N- (2-fluoro-4-(2-oxopyridin-1(2H)-yl)phenyl)-4-methoxypyrrolidine-1,2-dicarboxamide (PD 0348292), an orally efficacious factor Xa inhibitor

31 March 2020

1 reference

The dynamics of thrombin formation

31 March 2020

1 reference

Mechanisms of thrombus formation

31 March 2020

1 reference

Cofactor proteins in the assembly and expression of blood clotting enzyme complexes

31 March 2020

1 reference

Thrombin physiology and pathophysiology

31 March 2020

1 reference

What is all that thrombin for?

31 March 2020

1 reference

Factor Xa--a promising target for drug development

31 March 2020

1 reference

Isolation and characterization of antistasin. An inhibitor of metastasis and coagulation

31 March 2020

1 reference

12 December 2020

Comparison of the in vivo anticoagulant properties of standard heparin and the highly selective factor Xa inhibitors antistasin and tick anticoagulant peptide (TAP) in a rabbit model of venous thrombosis

1 reference

12 December 2020

1 reference

12 December 2020

Apixaban, an oral, direct inhibitor of activated Factor Xa.

1 reference

12 December 2020

Development of DX-9065a, a novel direct factor Xa antagonist, in cardiovascular disease.

1 reference

12 December 2020

Antistasin, a leech-derived inhibitor of factor Xa. Kinetic analysis of enzyme inhibition and identification of the reactive site

1 reference

12 December 2020

Transient interruption of arterial thrombosis by inhibition of factor Xa results in long-term antithrombotic effects in baboons

1 reference

12 December 2020

Nutrition classics from The Journal of Biological Chemistry 138:21-33, 1941. Studies on the hemorrhagic sweet clover disease. IV. The isolation and crystallization of the hemorrhagic agent by Harold A. Campbell and Karl Paul Link

1 reference

12 December 2020

"Normal" thrombin generation.

1 reference

12 December 2020

DU-176b, a potent and orally active factor Xa inhibitor: in vitro and in vivo pharmacological profiles

1 reference

12 December 2020

Rivaroxaban for thromboprophylaxis after orthopaedic surgery: pooled analysis of two studies.

1 reference

12 December 2020

Fondaparinux, a synthetic pentasaccharide: the first in a new class of antithrombotic agents - the selective factor Xa inhibitors

1 reference

12 December 2020

The amino acid sequence of antistasin. A potent inhibitor of factor Xa reveals a repeated internal structure

1 reference

12 December 2020

DX-9065a, a new synthetic, potent anticoagulant and selective inhibitor for factor Xa.

1 reference

12 December 2020

In-vitro profile and ex-vivo anticoagulant activity of the direct thrombin inhibitor dabigatran and its orally active prodrug, dabigatran etexilate

1 reference

12 December 2020

Biochemical and pharmacological characterization of YM-60828, a newly synthesized and orally active inhibitor of human factor Xa

1 reference

12 December 2020

Identifiers

DOI

10.1038/NRD3185

1 reference

Dimensions Publication ID

23 August 2017

1005450030

0 references

1 reference